Baclofen is NOT the safer option in patients with SVT
In patients with a history of supraventricular tachycardia, neither baclofen nor cyclobenzaprine can be definitively recommended as "safer," but baclofen carries specific cardiac risks that make it particularly concerning in this population.
Key Cardiac Concerns with Baclofen
Baclofen has documented cardiac toxicity that is directly relevant to SVT patients:
Supraventricular tachyarrhythmias: A case report documented that baclofen overdose resulted in rapid supraventricular tachyarrhythmia requiring medical intervention, with increased cardiac conduction times 1. This demonstrates baclofen can directly trigger the very arrhythmia your patient has a history of.
Severe bradyarrhythmias and cardiac arrest: Recent evidence shows baclofen withdrawal can cause life-threatening bradyarrhythmia and reduced cardiac output requiring inotropic support 2. This creates a dangerous clinical scenario where both toxicity AND withdrawal pose cardiac risks.
CNS depression effects: The FDA label warns about sedation and CNS depression 3, which can complicate arrhythmia management and monitoring.
Cyclobenzaprine's Cardiac Profile
While cyclobenzaprine also has cardiac concerns, they differ in nature:
Sodium channel blockade: Cyclobenzaprine can cause QRS prolongation and has potential for ventricular dysrhythmias, though cardiac toxicity from cyclobenzaprine alone is rare 4. The case report showing cardiac arrest involved massive overdose (combined with lacosamide) rather than therapeutic dosing.
Pharmacovigilance data: Recent FAERS analysis identified cardiac arrest as a signal, but also noted toxicity concerns primarily with overdose scenarios 5.
Critical Clinical Considerations
Neither medication is ideal for SVT patients, but the decision framework should be:
Avoid both if possible - Consider alternative muscle relaxants or non-pharmacologic approaches for spasticity/muscle spasm
If muscle relaxant is absolutely necessary:
- Cyclobenzaprine may have a marginally better profile at therapeutic doses in SVT patients, as its cardiac toxicity is primarily seen in overdose
- Baclofen's documented ability to trigger supraventricular tachyarrhythmias at therapeutic levels 1 makes it particularly problematic
If baclofen must be used:
- Start at lowest possible dose
- Ensure cardiac monitoring is available
- Never abruptly discontinue (withdrawal risks are severe 2)
- Monitor for both arrhythmia precipitation and CNS effects
Red flags requiring immediate cessation:
- New palpitations or documented SVT episodes
- Syncope or presyncope
- Significant bradycardia
The Bottom Line
The question asks which is "safer" - the answer is neither is truly safe in SVT patients, but baclofen's documented precipitation of supraventricular tachyarrhythmias 1 makes it the more problematic choice. The ACC/AHA/HRS guidelines for SVT management 6 do not address muscle relaxants because they are not indicated in arrhythmia management and should be avoided when possible in this population.
If you must choose between the two, cyclobenzaprine's cardiac risks appear more dose-dependent and overdose-related, whereas baclofen has triggered arrhythmias that required intervention even in acute toxicity scenarios. However, this is choosing between two suboptimal options - strongly consider alternative therapies for muscle spasm in SVT patients.